01 May, 2017 09:47 AM
Innate Immunotherapeutics Limited (ASX Code:IIL), together with a number of Australian, Canadian, and Danish scientific collaborators presented five posters at last week’s American Academy of Ne...read more
27 Apr, 2017 01:53 PM
RECENT EVENTS
CLINICAL TRIAL COMPLETED
On April 20, Innate Immunotherapeutics announced the last study-related clinical visit by patients suffering from Secondary Progressive Multiple Sclerosis ...read more
19 Apr, 2017 02:39 PM
The Board of Innate Immunotherapeutics Limited (“IIL” or “the Company”) has resolved to grant 500,000 options to the Company’s Chief Executive Officer, Mr. Simon Wilkinso...read more
10 Apr, 2017 02:18 PM
Innate Immunotherapeutics, together with a number of Australian, Canadian, and Danish scientific collaborators, has had multiple abstracts accepted for presentation at the American Academy of Neurolog...read more
17 Mar, 2017 08:12 AM
The Board of Innate Immunotherapeutics Limited (ASX:IIL) (“Innate”) has resolved to make a private placement (“Placement”) to raise gross proceeds of A$2,000,000.
Innate int...read more
16 Mar, 2017 08:32 AM
The securities of Innate Immunotherapeutics Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by th...read more
07 Mar, 2017 04:17 PM
Innate Immunotherapeutics Limited (ASX Code: IIL), together with a number of Australian, Canadian, and Danish scientific collaborators, has had multiple abstracts accepted for presentation at the Amer...read more